Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CanadaBis Capital Inc V.CANB

Alternate Symbol(s):  CNADF

CanadaBis Capital Inc. is a Canada-based vertically integrated cannabis company. The Company’s principal business is the production and sale of recreational cannabis and cannabis extracts. The Company operates through three segments: Cultivation and wholesale, Retail, and Extract. The Cultivation and wholesale segment is engaged in cultivating and distributing cannabis and cannabis products to and through, provincial liquor and cannabis boards, which are subsequently sold to end consumers. Its Retail segment is involved in the sale of cannabis and cannabis related products to end consumers on premise owned and operated by the Company. Its Extract segment comprised of wholesale product sales through its production facilities to distributors and licensed cannabis producers. The Company’s subsidiaries include Stigma Pharmaceuticals Inc., 1998643 Alberta Ltd., Full Spectrum Labs Ltd., 2103157 Alberta Ltd., and Goldstream Cannabis Inc.


TSXV:CANB - Post by User

Post by Oldschool2022on Dec 01, 2022 10:24pm
263 Views
Post# 35145219

$17 million gross revenue up from $8 million.

$17 million gross revenue up from $8 million.

Overall gross revenues for the year ended July 31, 2022 increased to $17.1 million from $8 million in the comparative period. This significant increase was due to sales from its new and existing SKUs launched under the Dab Bod Brand and the industry’s demand for new innovative products such as the High Priestess brand and the Infuse Pre-rolls. A 200% increase period over period due to sales growth in infuse pre- rolls, live resin vapes and shatter and moonrocks products. CanadaBis reported net revenues of $4,178,442 for the 2022 Q4 as compared to $1,663,630 for the comparative period in 2021. The Company has experienced growth in the existing Provinces such as Alberta, Ontario, Manitoba and British Columbia. Since the start of the 2022 fiscal year, the Company has shown growth in revenue period over period as demand for resin infuse pre-rolls rises. See Segmented Reporting section to this MD&A, for a more detailed discussion.

The Company continues to be profitable recognizing net income (loss) for three months ended July 31, 2022, of $481,758 compared to a net loss of $(1,195,906) in the comparative period. This resulted from a 169% increase in income resulted from increased sales to the Provinces from its hydrocarbon products and several new SKUs acceptance.

The Company currently owns a 66,000 square foot facility and approximately 44,000 square feet of the building has been developed and equipped for initial capacity to grow 225 kg of cannabis per year. Majority of the footprint is equipped and being used for production of Cannabis products such as extracts and Infused Pre rolls.

Effective November 26, 2020, the Company received its Cannabis 2.0 sales license, allowing it to sell Cannabis concentrates products to end users. This development has had a positive impact on the Company as it will no longer needs to engage third parties holding a Cannabis 2.0 sales license to bring its concentrates products to market.

<< Previous
Bullboard Posts
Next >>